The Specialty Pharmacy Review Board™ —Examining Emerging Therapies and Care Management Interventions for Alzheimer's Disease

• Release Date: September 1, 2017
• Expiration Date: March 31, 2019
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

REVIEW BOARD FACULTY

Steven G. Avey, MS, RPh, FAMCP Vice President, Specialty Pharmacy Programs MedImpact Healthcare Systems, Inc. Click here for biography John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health Click here for biography James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care Click here for biography Marwan Sabbagh, MD, FAAN, CCRI Karsten Solheim Chair for Dementia Professor of Neurology Director of the Alzheimer's and Memory Disorders Division Barrow Neurological Institute Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with Alzheimer’s Disease including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

Alzheimer's disease (AD) represents a significant driver of morbidity and mortality in the US, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. An estimated 5.3 million Americans were living with AD in 2015, and as many as 7.1 million will be diagnosed with the disease by 2025 according to the Alzheimer's Association. By 2050, that number may nearly triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease. Unsurprisingly, this considerable burden of illness associated with AD is also accompanied by extensive direct and indirect costs. This activity will provide the best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with AD.

The educational format of The Specialty Pharmacy Review Board™ will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Describe various diagnostic tools for Alzheimer’s Disease (AD) and evaluate their respective benefits and disadvantages for standardized use among network providers
• Describe the impact of care coordination in AD in terms of patient quality of life and disease outcomes
• Implement plan-wide initiatives to better coordinate care for AD among primary and ancillary providers in acute and long-term settings
• Appraise the novel mechanisms of action (MOAs) and clinical benefits of emerging disease-modifying agents for the management of AD
• Recommend benefit design strategies for emerging biologic and small-molecule AD therapies that encourage appropriate utilization while facilitating patient access and adherence
• Outline the components and benefits of an effective medication therapy management (MTM) program for AD
• Characterize the role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies for AD

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-17-099-H01-P.

Type of Activity: Knowledge

Nursing Continuing Education

Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. MER is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
This CE activity provides 1.0 contact hours of continuing nursing education.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily Medical Education Resources Inc., Impact Education, LLC, and/or Novartis Pharmaceuticals Corporation. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Impact Education, LLC, and/or Novartis Pharmaceuticals Corporation.  Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CPE credit for this activity. During the period September 1, 2017 through March 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.